Publication of may-june 2024

  • Onco-Hématologie : tour d'horizons
  • Rhumatologie : aujourd'hui et demain
  • Crise hospitalière et formation des médecins spécialistes
  • Ama Contacts - Alcool et maladie alcoolique

 

View the journal (french version)

Our journal

See all archives (french version)

Month's articles

Hématologie et Oncologie médicale

The management of chronic lymphocytic leukemia in clinical...

Chronic lymphocytic leukemia is the most common leukemia subtype, accounting for over one-third of leukemia cases in Belgium. Recent years have seen a significant expansion in the treatment range available to patients and clinicians. Today, we live in an era of targeted therapies and immunotherapies, relegating chemotherapy to very rare situations. These new treatments were shown to offer excellent prospects in terms of progression-free survival and quality of life for patients, but they have also introduced new toxicity profiles that clinicians must manage. This article sought to provide physicians with a condensed update on what they need to know about managing this disease in 2024.

Read more
Rheumatology

Rheumatology in the future

On the occasion of the ECU-UCL educational day on May 25, 2024, the author sought to predict the evolution of rheumatology by highlighting the decline in current rheumatic semiology, emergence of new diseases (particularly of environmental origin), contributions of network medicine, as well as the emergence of cell therapy.

Read more
Rheumatology

Arthritis treatment in 2024

On the occasion of the ECU-UCL educational day held on May 25, 2024, the author summarized the 2024 therapeutic approach to arthritis, covering both traditional pharmacological treatments and new targeted strategies based on biological agents and JAK kinase inhibitors.

Read more
Hématologie et Oncologie médicale

Innovations in multiple myeloma management in 2024: the key...

In recent years, new therapies, mainly consisting of monoclonal antibodies like daratumumab and isatuximab, have revolutionized the management of patients with multiple myeloma (MM). Despite these advances, MM remains incurable, and patients who have become refractory to the three therapeutic classes of drugs, including proteasome inhibitors, immunomodulators, and monoclonal antibodies, have a particularly poor prognosis, which highlights the need for new treatment strategies. The development of novel immunotherapeutic approaches, such as antibody-drug conjugates, bispecific antibodies, and CAR T-cells, marks a turning point for heavily pre-treated patients, while revolutionizing their future. In this article, we have reviewed the contributions of these therapies to the current treatment landscape.

Read more
Hématologie et Oncologie médicale

Myeloproliferative neoplasia: from clinical practice... to...

Classic BCR::ABL1 negative myeloproliferative neoplasms (MPN) include polycythemia vera, essential thrombocythemia, and myelofibrosis. These diseases arise from the clonal proliferation of a single hematopoietic stem cell which has acquired a driver mutation. They are considered chronic diseases, manifesting by symptoms listed in the MPN-10 score, thrombosis or, more rarely, hemorrhage. These diseases can progress to myelofibrosis or blast phase, with a guarded prognosis. Diagnosis requires bone marrow biopsy. First-line treatments consist of low-dose aspirin, phlebotomies in polycythemia vera, anticoagulation, and cytoreduction using hydroxyurea in certain situations. Treatments for myelofibrosis include allogeneic stem cell transplantation for curative purposes or JAK2 inhibitors to reduce both symptoms and spleen size. Recent research advances in a better understanding of the mutated protein have led to the development of new treatments aimed at eradicating the mutated cells, including human monoclonal antibodies and bispecific antibodies. These promising targeted treatments are currently undergoing clinical trials.

 

Read more
Économie de la santé

Hospital on-call duty: Solidarity often pays off!

This article has attempted to address a contentious issue regarding on-call duty allocation in hospitals. Let us consider a hospital scenario with 20 clinical specialist assistant candidates (MACCS), consisting of 10 juniors in their core year of general internal medicine and 10 seniors specializing in areas like cardiology, gastroenterology, pneumology, etc. These MACCS are distributed across various departments, each comprising 1 to 5 MACCS, with varying proportions of juniors and seniors. Every night or weekend, one of these doctors had to be on call to provide permanent hospital patient care that was followed by a recuperation day. A discussion is currently underway as to whether senior MACCS should participate as much as junior MACCS in on-call duty. These senior MACCS receive 12% higher remuneration than younger staff, while they assist doctors in carrying out technical examinations during the day as part of their training. Will it cost more to the institution if the 10 senior staff members take part in general on-call duty? How will their absence during recuperation affect their work and training? Would departments with more senior staff face disadvantages? How would you address these questions? Some might be rather pessimistic, but how does it actually look reality?

Read more
See all articles

STOPP/START.v2

The tool STOPP / START.v2 allows evaluation of drug treatments prescribed to patients age 65 and older.

 

This tool, designed for all care settings, stimulates thinking and challenging medication taken by patients, especially drugs forcardiovascular and nervous system.

View more

Become an author

Whether you are active physician, retired physician , Assistant , Student, ...
Feel free to submit an article in your field of expertise.

View more (french version)